BioRestorative Therapies (BRTX) expects to provide a positive clinical pipeline update before market open on Thursday, February 27, 2025. “We very much look forward to updating investors on some recent meaningful key developments with respect to our clinical pipeline and review some additional positive events related to BRTX-100 on Thursday,” said Lance Alstodt, Chief Executive Officer of BioRestorative. “We are thrilled to be in a position that reflects the very solid work of our scientific team over the last several years come to fruition and excited to see that positive momentum continue.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRTX:
- BioRestorative Therapies- BRTX-100 program receives FDA Fast Track designation
- Promising Phase 2 Results and Market Dynamics Boost Confidence in BioRestorative Therapies
- BioRestorative Therapies Issues Regulation FD Disclosure
- BioRestorative Therapies announces new data on BRTX-100 presented at ORS 2025
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue